Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-7

First 7 Last

Share
Profile

Follow
Hasnuhana

107 Posts.

9

26/07/21

16:27

Post #: 54782205
Share

Originally posted by JPGuru: ↑

I feel lucky to cancel my buy order today.... as already in RED by 50% + it would be disaster if I bought today. I don't see this one going anywhere up in near future without significant sell or getting FDA HDE approval... IMO.

They had 3m cash burn in 3 months and no sell. Also they have no courtesy to tell how many units they sold in last quarter...... IMO.

They still talk about Covid and not able to submit FDA application response .... then how on earth they spend 3m on staff when there is no output between last quarter and this quarter... IMO.

They had four headline activity and none of them completed task as below:

Europe - screen continue - This is going on for ages not new task and screening is done by hospital not OSL in my opinion.
APEC: - Discussion with hospital to get OSPREY implemented - This task is ongoing and still not competed in 3 months.
USA - FDA work on going - this is long outstanding task and still ongoing... WTH??
Clinical Development - ongoing task -- nothing completed in 3 months

So in three months they still have task outstanding that they had in last quarter but they spend $3m.. IMO.

IMO... TGA withdrawal was another disappointment without any logical and clear reasoning and it was done by Nigel so can't blame previous management.... and he should be able to explain why it was done not just some hypothesis that he believes it won't get approved based on their submission...IMO.

Market updates are not provided regularly so what on earth they are doing if they can't keep shareholders engaged with the company. They have only 4 quarter worth of cash left which means they need to start selling more than 100 units (@30k each) every quarter to pay for their wages and staying in market positive or do the capital raise again... IMO... can we assume that they will be able to sell 400 - 500 units within next 12 month (4 quarter) and if not then CR is on the card...... IMO.

I have to put this one under the drawer and wait for CAP raise or any unknown positive announcement.

GLAH.

Expand

I absolutely agree with your points. All very true and the management is not showing any progress There's nothing new in today's announcement. Surely Covid cant be so disruptive in selling a treatment like OncoSil for LAPC which will kill someone faster. I feel totally dejected and let down and cant believe I am still holding. I do not want to incur a major loss so cant sell it either.

OSL Price at posting: 5.0¢ Sentiment: Sell Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

NOX

Noxopharm gets HERACLES autoimmune trials started with first human doses

AII

Inside the depths of Panasqueira: A legacy carved in rock

WCE

'Exceptional start' for West Coast Silver in Elizabeth Hill's maiden drill run

MGX

Mount Gibson gets into gold with 'attractive' $50M Central Tanami joint venture

First 7 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.20		Change 0.090(8.11%)		Mkt cap ! $22.68M

Open	High	Low	Value	Volume
$1.12	$1.21	$1.12	$64.42K	55.62K

Buyers (Bids)

No.	Vol.	Price($)
2	10305	$1.16

Sellers (Offers)

Price($)	Vol.	No.
$1.20	4271	3

View Market Depth

No.	Vol.	Price($)
2	9710	1.160
2	12390	1.150
1	2000	1.140
1	5000	1.135
2	1860	1.125

Price($)	Vol.	No.
1.200	9271	4
1.205	23550	2
1.210	1721	1
1.220	5000	3
1.250	13031	3

Last trade - 12.12pm 16/07/2025 (20 minute delay)

OSL (ASX) Chart

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-7

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Noxopharm gets HERACLES autoimmune trials started with first human doses

Inside the depths of Panasqueira: A legacy carved in rock

'Exceptional start' for West Coast Silver in Elizabeth Hill's maiden drill run

Mount Gibson gets into gold with 'attractive' $50M Central Tanami joint venture

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-7

Top Stories

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Noxopharm gets HERACLES autoimmune trials started with first human doses

Inside the depths of Panasqueira: A legacy carved in rock

'Exceptional start' for West Coast Silver in Elizabeth Hill's maiden drill run

Mount Gibson gets into gold with 'attractive' $50M Central Tanami joint venture

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News